GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging Studies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Third-generation neuroimaging research has been enriched by advances in magnetic resonance spectroscopy (MRS) measuring the concentration of important neurotrasmitters, such as the inhibitory amino acid GABA. Here, we performed a systematic mini-review on brain MRS studies measuring GABA concentration in patients affected by schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We wondered whether multimodal investigations could overcome intrinsic technical limits of MRS giving a broader view of mental disorders pathogenesis. In SZ, unimodal studies gave mixed results, as increased, decreased, or unaltered GABA levels were reported depending on region, disease phase, and treatment. Conversely, multimodal results showed reduced level of glutamate, but not of GABA, in patients mirrored by in vitro biochemical findings revealing hippocampal reduction in glutamate signaling in SZ, and no deficits in GABA synthesis. Moreover, a mouse model confirmed the unique pathological characteristic of glutamate function in SZ. Unimodal studies in BD revealed again, inconsistent results, while no multimodal investigations including MRS on GABA exist. In MDD, unimodal studies could not differentiate patients from controls nor characterize high-risk subjects and remitted patients. However, a multimodal study combining functional magnetic resonance imaging and MRS revealed that cingulate cortex activity is related to glutamate, N-acetylaspartate levels and anhedonia in patients, and to GABA concentration in healthy subjects, improving the distinction between MDD and physiology. Overall, our results show that unimodal studies do not indicate GABA as a biomarker for the psychiatric disorders considered. Conversely, multimodal studies can widen the understanding of the link between psychopathology, genetics, neuroanatomy, and functional-biochemical brain activity in mental disorders. Although scarce, multimodal approaches seem promising for moving from GABA MRS unimodal-descriptive to causal level, and for integrating GABA results into a more comprehensive interpretation of mental disorder pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What we can do and what we cannot do with fMRI
Logothetis, N. K. (2008) · Nature · doi:10.1038/nature06976 · Cited by 3,612 · cited 1×
“Indeed, fMRI can differentiate neural response patterns induced by stimulation (56), in vitro biochemistry allows higher resolution spatial information and correlations between MRS results and biochemical activity of the brain, while genotyping can elucidate the genetic correlates of GABAergic transmission.”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 1×
“, depressed/remitted) at scan time (see Table 2) allows us to support the idea that GABA level identifies the state of being ill, and is not a trait marker for diagnosis, since physiological concentration has been described in the majority of studies including MDD patients during the remission phase (44, 49, 50, 53, 5…”
BackgroundYoon, J. H., Maddock, R. J., Rokem, A., Silver, M. A., Minzenberg, M. J., Ragland, J. D., & Carter, C. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6158-09.2010 · Cited by 408 · cited 2×
“Specifically, GABA was reduced in medial frontal cortex (MFC) (29, 30) and occipital cortex (OC) (32, 33), and the result was modulated by age in MFC (29, 30) and not affected by current medication type or dosage in OC (32, 33).”
BackgroundResultWalter, M., Henning, A., Grimm, S., Schulte, R. F., Beck, J., Dydak, U., Schnepf, B., Boeker, H., Boesiger, P., & Northoff, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.39 · Cited by 306
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Anterior Cingulate Cortexγ-Aminobutyric Acid in Depressed Adolescents: Relationship to Anhedonia
Gabbay, V. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.131 · Cited by 201
Neurochemistry of major depression: a study using magnetic resonance spectroscopy
Godlewska, B. R., Near, J., & Cowen, P. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3687-y · Cited by 97 · cited 1×
“4) Antidepressant: 6 (46), mood stabilizers: 12 (92) Typ, Atyp, Both: Na; None: 0 (0) POC, Thal, whole brain Whole brain: GABA_BD_ antipsy < GABA_BD_ noantipsy”
Statin and Aspirin Use and the Risk of Mood Disorders among Men
Williams, L. J., Pasco, J. A., Mohebbi, M., Jacka, F. N., Stuart, A. L., Venugopal, K., O’Neil, A., & Berk, M. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw008 · Cited by 32
Cited by
Kawwass, J. F., Sanders, K. M., Loucks, T. L., Rohan, L. C., & Berga, S. L. (2017) · Human Reproduction · doi:10.1093/humrep/dex086 · Cited by 79
“…levels in the CSF of women with PCOS may explain, at least in part, the altered emotional and cognitive processing and the increased prevalence of gender identity issues and mental health disorders in this population (Chiapponi et al., 2016; Deligiannidis et al., 2016; Michopoulos et al., 2013).”
Lopes Sakamoto, F., Metzker Pereira Ribeiro, R., Amador Bueno, A., & Oliveira Santos, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104395 · Cited by 49
Polypharmacy- Purpose, Benefits and Limitations
Grover, D., Tom, M., Maguire, G., & Stahl, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220107153813 · Cited by 7
Metadata
- Authors
- Chiapponi, C., Piras, F., Piras, F., Caltagirone, C., & Spalletta, G.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2016-04-19
- Volume
- 7
- Pages
- 61-61
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2340922959
- Cited by
- 104
- References
- 9
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.